Last reviewed · How we verify
Pantoprazole low dose
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related gastrointestinal disorders.
At a glance
| Generic name | Pantoprazole low dose |
|---|---|
| Also known as | zurcal |
| Sponsor | Sherief Abd-Elsalam |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Pantoprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric acidity and is used to treat acid-related gastrointestinal disorders. The low-dose formulation maintains therapeutic efficacy while potentially reducing systemic exposure and associated risks.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Acid-related gastrointestinal disorders
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Flatulence
Key clinical trials
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding (NA)
- Pantoprazole in Cisplatin Nephrotoxicity (PHASE3)
- Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication (NA)
- Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants (PHASE1)
- Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment (NA)
- Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects (PHASE1)
- Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |